Core Viewpoint - The company has received clinical trial approval for its long-acting bispecific antibody QX027N, which is intended for the treatment of asthma and atopic dermatitis, marking a significant advancement in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The National Medical Products Administration has granted clinical trial implicit approval for QX027N, with acceptance numbers CXSL2500757 and CXSL2500758 [1] - QX027N represents a key achievement in the company's bispecific antibody research and signifies further progress in its strategic focus on respiratory and dermatological diseases [1] - The company aims to address the clinical needs of hundreds of millions of asthma and atopic dermatitis patients globally by advancing innovative therapies for more effective, safer, and more convenient treatment options [1]
荃信生物-B(02509.HK)长效双抗QX027N获得两项临床试验默示许可